Abstract
Since the first transradial percutaneous coronary intervention in 1992 by Kiemenij, this technique has been performed heterogeneously around the world with increasing interest due to recent reports in the literature. I ndeed, this approach decreases access site complications and major bleeding and increases patient comfort. All patient subgroups benefit from this approach, especially in cases of acute coronary syndromes where the risk of bleeding is highest. In this review, we will address the debate between femoralists and radialists with regard to pre-RIVAL studies and including the RIVAL randomised trial. The aim of this literature review is to demonstrate that ignoring the transradial approach can no longer be justified.